Article Details

Chinese Biotechs Garner Millions for Shingles Vaccine Candidate to Rival GSK's Shingrix

Retrieved on: 2022-07-22 14:58:02

Tags for this article:

Click the tags to see associated articles and topics

Chinese Biotechs Garner Millions for Shingles Vaccine Candidate to Rival GSK's Shingrix. View article details on hiswai:

Excerpt

Vaccines developer Maxvax raised nearly CNY500 million (approx. $74 million) from a Series B funding round led by China Life Private Equity Investment ...

Article found on: www.biospace.com

View Original Article

This article is found inside other hiswai user's workspaces. To start your own collection, sign up for free.

Sign Up